PortViewPortView
Organogenesis logo

Organogenesis (ORGO) Stock Analysis

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

$1.69+3.98%
1-year price historyRange $1.63 – $6.54
52-week range$1.69
$1.54$7.08

What Organogenesis does

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

Key metrics

Market cap
$218.09M
P/E (TTM)
56.50
EPS (TTM)
$0.03
Beta
1.32
Dividend yield
0.00%
Revenue / share
$3.55
50-day avg
$2.21
200-day avg
$3.16
52-week high
$7.08
52-week low
$1.54
CEO
Gary S. Gillheeney

ETFs linked to ORGO

Broad-market and Healthcare sector ETFs an investor holding Organogenesis is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ORGO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ORGO in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Organogenesis?
Organogenesis trades under the ticker ORGO on NASDAQ.
Which exchange is ORGO listed on?
ORGO is listed on NASDAQ.
What sector does Organogenesis operate in?
Organogenesis is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
How can PortView help analyze ORGO in a portfolio?
PortView shows ORGO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.